MedPage Today on MSN2d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® ...
The Lancet2d
Increasing walking capacity in patients with peripheral artery disease
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Clinical Advisor7d
Could GLP-1RAs be a Novel Pharmacological Intervention for AUD?
Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.
TMCnet5d
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
MedPage Today3d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
Out of 1,363 screened candidates, 792 participants were selected and randomized 1:1 to subcutaneous semaglutide (1.0 mg once weekly) or placebo for 52 weeks. This cohort was 25% women and had a ...
Renal & Urology News28d
Semaglutide May Reduce Craving in Alcohol Use Disorder
The researchers found that low-dose semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1 mg for one week) reduced the amount of alcohol consumed during a posttreatment laboratory ...